Skip to content
StackItSmart
CCase reports / series
High riskPotentially lethalCardiotoxicNeuropsychiatricHepatotoxic

DNP

2,4-Dinitrophenol

2,4-Dinitrophenol (DNP) is an industrial chemical (historically a herbicide, dye/explosives intermediate, and briefly a 1930s anti-obesity drug) that is misused for rapid fat loss because it uncouples mitochondrial oxidative phosphorylation, forcing the body to burn energy as heat instead of storing it as ATP. It is one of the most dangerous substances in this category: there is no antidote, an extremely narrow margin between a dose that causes fat loss and one that kills, and marked person-to-person variability in how it is handled. The main danger is uncontrollable hyperthermia (body temperatures over 40-41.5 C) accompanied by tachycardia, profuse sweating, rapid breathing, metabolic acidosis, agitation, and progression to seizures, cardiac arrest, multi-organ failure, and death, sometimes after only a small number of tablets. Poisons-centre data from multiple countries report case-fatality rates around 11-17%. Because it is a heat-generating metabolic poison rather than a hormone, its risks are acute-toxicity and death, not the endocrine effects of steroids. There is no established safe dose; deaths have occurred at doses users considered ordinary. If someone who has taken DNP develops fever, a racing heart, agitation, or breathing difficulty, this is a medical emergency requiring immediate emergency care.

Clinical readoutPED-adjacent · mitochondrial-uncoupler
Hepatic strainVery high
CardiovascularVery high
HPTA suppressionNone
Half-life
3.6 wk
Route
Oral
Evidence
C
Active
Prolonged and cumulative
3.6 wk7.1 wk10.7 wk14.3 wk17.9 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not precisely established in humans; elimination is slow and persistent. In a series of acute poisonings, plasma DNP was still measurable up to about 25 days after exposure, with only roughly half cleared within the first 3 days [PMID 26238547]. This long, ill-defined half-life means repeated dosing causes accumulation.
Pharmacology

Mechanism of action

DNP is a protonophore that carries hydrogen ions (protons) across the inner mitochondrial membrane, dissipating the electrochemical proton gradient that ATP synthase normally uses to make ATP. This "uncouples" oxidative phosphorylation: cells keep burning substrate and consuming oxygen, but the energy is released as heat rather than captured as ATP. The result is a hypermetabolic state with greatly increased basal metabolic rate, oxygen consumption, and heat production. Because thermogenesis is driven at the cellular level, the body's normal cooling and thermoregulatory mechanisms cannot keep up, producing the characteristic and frequently fatal hyperthermia. The same energy deficit drives compensatory tachycardia, tachypnoea, and lactic/metabolic acidosis.
Kinetics

Pharmacokinetics

Half-life

Not precisely established in humans; elimination is slow and persistent. In a series of acute poisonings, plasma DNP was still measurable up to about 25 days after exposure, with only roughly half cleared within the first 3 days [PMID 26238547]. This long, ill-defined half-life means repeated dosing causes accumulation.

Active duration

Prolonged and cumulative. Because clearance is slow, metabolic and hyperthermic effects can persist for days and worsen with repeated intake before a person realises they are in danger [PMID 26238547].

Route

Oral (capsules/powder) is the usual route of misuse; historical exposures also occurred via dermal and inhalational/occupational contact [PMID 21739343][PMID 26238547].

Metabolism & clearance

Hepatic phase I reduction of nitro groups to amino-nitrophenol metabolites (e.g., 2-amino-4-nitrophenol) and phase II conjugation (glucuronide and sulfate), with renal excretion; parent compound and metabolites detectable in blood, urine, bile and gastric contents at autopsy [PMID 17389084]. Overall body clearance is slow and persistent [PMID 26238547]. PK is documented here for clinical monitoring/washout reasoning and clinician discussion only.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Marked increase in basal metabolic rate, oxygen consumption and heat production due to uncoupled oxidative phosphorylation [PMID 34812657][PMID 21739343]
  • Body-fat and body-weight reduction driven by the hypermetabolic state, historically the reason for its use as a slimming/'fat-burning' agent [PMID 34812657][PMID 21739343]
  • Heat generation (thermogenesis), which is the same mechanism responsible for its life-threatening hyperthermia [PMID 21739343]
  • Profuse sweating and a sensation of feeling hot/flushed [PMID 24957806]
Safety

Adverse effects by system

Cardiovascular

Tachycardia is one of the most common features (about 43% of reported exposures) and is an independent predictor of death in the adjusted multivariate model; hypertension is also common in serious poisoning and was associated with death in univariate analysis, though it did not remain significant once other predictors were adjusted for. Fatal cases have progressed to cardiac arrest [PMID 24957806][PMID 33021407][PMID 30573533].

Hepatic

Historically DNP is recognised as hepatotoxic, and hepatic injury is described as part of the multi-organ failure seen in severe poisoning; dedicated human dose-response data are limited and this is reported largely within toxicology reviews and fatal cases rather than controlled studies [PMID 21739343].

Endocrine / HPTA

DNP is a metabolic uncoupler, not a hormonal/androgenic agent, and there is no adequate human evidence that it directly suppresses the hypothalamic-pituitary-testicular (HPT) axis. Its dangers are acute metabolic toxicity rather than endocrine suppression [PMID 21739343][PMID 34812657].

Reproductive

No adequate human data on reproductive or fertility effects of DNP; this cannot be characterised from the available primary literature.

Neuropsychiatric

Agitation and confusion are frequently reported and are independent predictors of mortality; restlessness/akathisia and headache also occur [PMID 33021407][PMID 24957806].

Renal

Metabolic acidosis and raised lactate are common in serious poisoning and predict death; acute kidney injury can occur secondary to hyperthermia and rhabdomyolysis, though direct human renal-specific data are limited [PMID 33021407].

Hematologic

Methemoglobinaemia is documented in DNP toxicity, and dinitrophenols have historically been associated with lowered leucocyte counts (agranulocytosis); the leucopenia signal rests on older/mechanistic evidence rather than modern controlled human data [PMID 21739343][PMID 23429343].

Dermatologic

Sweating/diaphoresis is characteristic; skin discolouration or rash occurs in roughly a quarter of exposures, and yellow staining of skin and viscera (DNP is a yellow dye) is described at autopsy [PMID 24957806][PMID 16803658].

Recovery

HPTA suppression & recovery

Suppression: No adequate human data indicating direct HPTA suppression - DNP is a mitochondrial uncoupler, not an androgen or SERM-requiring compound, so classic steroid-style HPTA suppression is not an established feature

Because there is no evidence DNP directly suppresses the HPT axis, SERM-based 'recovery' is not an applicable framework and no such protocol is described here. Any hormonal or fertility concerns after use, or after the severe metabolic stress of an overdose, should be evaluated and managed by an endocrinologist. Consistent with a conservative single-SERM stance, dual-SERM protocols are out of scope [PMID 21739343].

Bloodwork & vitals

Monitoring

Recommended labs & checks
Core temperature (continuous)Arterial/venous blood gas with lactate and pH (metabolic acidosis)Serum electrolytes and glucose (hypoglycaemia is associated with death)Renal function and creatine kinase (rhabdomyolysis/acute kidney injury)Liver function testsFull blood count including differential (leucopenia) and methaemoglobin levelECG and cardiac monitoringWhere available, plasma DNP concentration to gauge severity and clearance

Cadence: DNP misuse cannot be safely 'monitored' on a routine outpatient schedule - it has no safe dose and no antidote. Any known ingestion with symptoms is an emergency requiring continuous in-hospital monitoring. The safest action is not to use it and to seek medical care for any exposure.

Warning signs — seek care
  • Fever or feeling very hot, flushed skin, heavy sweating
  • Fast or pounding heart, chest discomfort
  • Rapid or laboured breathing
  • Agitation, confusion, restlessness
  • Yellow discolouration of skin or eyes
  • Muscle pain or dark urine (possible rhabdomyolysis)
  • Nausea, vomiting, abdominal pain, headache
  • Any of these after taking DNP means call emergency services immediately - deterioration can be rapid and irreversible
Do not use if

Contraindications

  • There is no safe therapeutic use of DNP as a weight-loss agent; it is not an approved medicine and its use for slimming is associated with death even at commonly taken amounts [PMID 21739343][PMID 27045052]
  • Any pre-existing cardiovascular disease, arrhythmia or hypertension (drug causes tachycardia/hypertension and cardiac arrest) [PMID 33021407][PMID 30573533]
  • Conditions impairing heat dissipation or hydration, and hot environments/physical exertion (compounds the lethal hyperthermia) [PMID 21739343]
  • Hepatic or renal impairment (impaired clearance and organ vulnerability in a hypermetabolic state) [PMID 26238547][PMID 33021407]
  • Concurrent serotonergic/stimulant or other thermogenic agents, and psychiatric vulnerability given agitation/confusion (co-ingestants have contributed to fatal outcomes) [PMID 17389084][PMID 33021407]
Combinations

Interaction profile

  • ContraindicatedWith an anabolic steroid: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • There is no established safe dose of DNP and no antidote; the single most protective step is not to take it. Deaths have followed only a small number of tablets [PMID 27045052][PMID 30573533].
  • Treat any fever, racing heart, agitation, heavy sweating or breathing difficulty after taking DNP as a life-threatening emergency and call emergency services immediately - deterioration to hyperthermia, seizures, cardiac arrest and death can be rapid and irreversible [PMID 21739343][PMID 33021407].
  • Tell emergency clinicians exactly what was taken; management is supportive (aggressive external/internal cooling, fluids, correction of acidosis, intensive-care monitoring). There is no proven antidote, and dantrolene has failed in reported cases [PMID 30573533][PMID 30948257].
  • Because DNP is eliminated slowly and accumulates, danger can build over days of repeated dosing; effects and hyperthermia risk persist even after stopping [PMID 26238547].
  • Heat, exertion, dehydration, and other stimulant/thermogenic or serotonergic substances all worsen the risk of fatal hyperthermia; co-ingestants have contributed to deaths [PMID 33021407][PMID 17389084].
  • This is educational information, not medical advice, and does not create a doctor-patient relationship. DNP carries a high risk of death; consult a qualified physician, and seek emergency care for any exposure. 21+ only.
Evidence

Citations (11)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    DNP uncouples mitochondrial oxidative phosphorylation, producing a hypermetabolic state, and is misused as a weight-loss/'fat-burning' agent despite an unacceptably high rate of serious adverse effects; the classic toxicity is hyperthermia, tachycardia, diaphoresis and tachypnoea progressing to death, with 62 published deaths reviewed and a history of fatalities since the early twentieth century.

    Meta-analysis2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of deathPMID 21739343 ↗

  2. 02

    DNP reduces body weight and body fat by uncoupling oxidative phosphorylation but carries severe dose-related toxicity; international poisons-centre data show rising exposures and a high case-fatality (~11.9%).

    CohortPMID 34812657 ↗

  3. 03

    In US and UK poisons-centre data, case fatality was high (US 11.6%, UK 16.9%); acidosis, tachycardia, agitation/confusion and hyperpyrexia are independent predictors of death, and hypoglycaemia, hypertonia and raised lactate are associated with death.

    CohortToxicoepidemiology and predictors of death in 2,4-dinitrophenol (DNP) toxicityPMID 33021407 ↗

  4. 04

    Common clinical features of DNP exposure include fever (47%), tachycardia (43%), sweating (37%), nausea/vomiting (27%), skin discolouration or rash (23%), breathing difficulty (23%), abdominal pain (23%), agitation (13%) and headache (13%), with a 17% fatality rate and increasing frequency of severe toxicity.

    CohortPMID 24957806 ↗

  5. 05

    DNP is extremely toxic in overdose with a narrow therapeutic window and marked interindividual variability in metabolism; no antidote exists and overdose is often fatal.

    Case reportPMID 27045052 ↗

  6. 06

    Acute DNP poisoning can produce uncontrolled hyperthermia (to 41.5 C) and cardiac arrest with death despite aggressive cooling; dantrolene was ineffective.

    Case reportPMID 30573533 ↗

  7. 07

    DNP toxicity clinically produces hyperthermia (to ~40 C) and metabolic acidosis and can be fatal within hours; treatment is supportive with no specific reversal therapy.

    Case seriesPMID 30948257 ↗

  8. 08

    Two deaths attributed to DNP used for weight loss showed markedly elevated body temperature, rapid pulse and respiration, and yellow colouring of the viscera at autopsy, with admission blood DNP concentrations of 36.1 and 28 mg/L.

    Case seriesPMID 16803658 ↗

  9. 09

    DNP undergoes phase I and phase II metabolism (e.g., 2-amino-4-nitrophenol plus glucuronide/sulfate conjugates) detectable in blood, urine, bile and gastric contents; co-ingestants can contribute to fatal outcomes.

    Case reportPMID 17389084 ↗

  10. 10

    Elimination of DNP is slow and persistent, with plasma toxin measurable up to about 25 days after acute poisoning and roughly half cleared within 3 days; higher initial plasma concentration correlates with higher body temperature.

    CohortPMID 26238547 ↗

  11. 11

    Dinitrophenols produce cataracts and lower leucocyte counts and act by inhibiting oxidative phosphorylation (mechanistic/toxicological basis).

    PreclinicalPMID 23429343 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice